CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Insulin Peglispro +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02197520
NCT02197520Phase 1Completed
CompareCT.gov

The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on Insulin Sensitivity and the Effect of Prandial Insulin Lispro in Patients With Type 2 Diabetes Mellitus

Eli Lilly and Company·interventional·Posted Jul 22, 2014·Updated Nov 1, 2018

In Brief

A Phase 1 clinical trial evaluating Insulin Peglispro, Insulin Glargine, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study will look into insulin sensitivity (how the body responds to insulin) and effects of meals on type 2 diabetics comparing insulin peglispro to insulin glargine. The study has two treatment periods, each of which will last about four weeks. One drug (insulin peglispro or insulin glargine) will be administered in each period. Participants will receive both drugs during the study. Participants may remain on stable dose metformin, as prescribed by their personal physician.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 22, 2014
Enrollment StartJul 1, 2014
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.9 years ago

Interventions

Insulin Peglisprodrug

Administered subcutaneously (SC), (U-100 formulation)

Insulin Glarginedrug

Administered subcutaneously (SC), (U-100 formulation)

Insulin Lisprodrug

Administered subcutaneously (SC), (U-100 formulation)